BeiGene, Ltd.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, VRTX has a market cap of 113.5B. Regarding current trading prices, BGNE is priced at $184.71, while VRTX trades at $441.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas VRTX's P/E ratio is -115.36. In terms of profitability, BGNE's ROE is -0.12%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, BGNE is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, REGN has a market cap of 52B. Regarding current trading prices, BGNE is priced at $184.71, while REGN trades at $489.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas REGN's P/E ratio is 12.44. In terms of profitability, BGNE's ROE is -0.12%, compared to REGN's ROE of +0.15%. Regarding short-term risk, BGNE is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BGNE is priced at $184.71, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BGNE's ROE is -0.12%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BGNE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALNY has a market cap of 39.7B. Regarding current trading prices, BGNE is priced at $184.71, while ALNY trades at $304.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ALNY's P/E ratio is -140.35. In terms of profitability, BGNE's ROE is -0.12%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, BGNE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ARGX has a market cap of 35B. Regarding current trading prices, BGNE is priced at $184.71, while ARGX trades at $573.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ARGX's P/E ratio is 35.00. In terms of profitability, BGNE's ROE is -0.12%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, BGNE is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, BGNE is priced at $184.71, while BNTX trades at $95.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BNTX's P/E ratio is -26.39. In terms of profitability, BGNE's ROE is -0.12%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, BGNE is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BGNE is priced at $184.71, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BGNE's ROE is -0.12%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, BGNE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RPRX has a market cap of 18.5B. Regarding current trading prices, BGNE is priced at $184.71, while RPRX trades at $32.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RPRX's P/E ratio is 13.42. In terms of profitability, BGNE's ROE is -0.12%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, BGNE is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, UTHR has a market cap of 14.4B. Regarding current trading prices, BGNE is priced at $184.71, while UTHR trades at $318.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas UTHR's P/E ratio is 12.71. In terms of profitability, BGNE's ROE is -0.12%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BGNE is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SMMT has a market cap of 13.4B. Regarding current trading prices, BGNE is priced at $184.71, while SMMT trades at $18.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SMMT's P/E ratio is -53.57. In terms of profitability, BGNE's ROE is -0.12%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, BGNE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, GMAB has a market cap of 12.9B. Regarding current trading prices, BGNE is priced at $184.71, while GMAB trades at $20.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas GMAB's P/E ratio is 12.25. In terms of profitability, BGNE's ROE is -0.12%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, BGNE is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BGNE is priced at $184.71, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BGNE's ROE is -0.12%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BGNE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, INCY has a market cap of 12.6B. Regarding current trading prices, BGNE is priced at $184.71, while INCY trades at $65.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas INCY's P/E ratio is 325.30. In terms of profitability, BGNE's ROE is -0.12%, compared to INCY's ROE of +0.01%. Regarding short-term risk, BGNE is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, EXEL has a market cap of 11.7B. Regarding current trading prices, BGNE is priced at $184.71, while EXEL trades at $43.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas EXEL's P/E ratio is 19.65. In terms of profitability, BGNE's ROE is -0.12%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, BGNE is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, BGNE is priced at $184.71, while BMRN trades at $58.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BMRN's P/E ratio is 21.35. In terms of profitability, BGNE's ROE is -0.12%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, BGNE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRNA has a market cap of 10.3B. Regarding current trading prices, BGNE is priced at $184.71, while MRNA trades at $26.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MRNA's P/E ratio is -2.94. In terms of profitability, BGNE's ROE is -0.12%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, BGNE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ASND has a market cap of 9.8B. Regarding current trading prices, BGNE is priced at $184.71, while ASND trades at $162.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ASND's P/E ratio is -24.71. In terms of profitability, BGNE's ROE is -0.12%, compared to ASND's ROE of +1.91%. Regarding short-term risk, BGNE is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BGNE is priced at $184.71, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BGNE's ROE is -0.12%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BGNE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BGNE is priced at $184.71, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BGNE's ROE is -0.12%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, BGNE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CORT has a market cap of 8.2B. Regarding current trading prices, BGNE is priced at $184.71, while CORT trades at $77.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CORT's P/E ratio is 67.42. In terms of profitability, BGNE's ROE is -0.12%, compared to CORT's ROE of +0.20%. Regarding short-term risk, BGNE is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BGNE is priced at $184.71, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CERE's P/E ratio is -16.47. In terms of profitability, BGNE's ROE is -0.12%, compared to CERE's ROE of -0.43%. Regarding short-term risk, BGNE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, BGNE is priced at $184.71, while ROIV trades at $10.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ROIV's P/E ratio is -10.97. In terms of profitability, BGNE's ROE is -0.12%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, BGNE is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, BGNE is priced at $184.71, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, BGNE's ROE is -0.12%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, BGNE is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, TECH has a market cap of 7.6B. Regarding current trading prices, BGNE is priced at $184.71, while TECH trades at $48.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas TECH's P/E ratio is 57.62. In terms of profitability, BGNE's ROE is -0.12%, compared to TECH's ROE of +0.06%. Regarding short-term risk, BGNE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RVMD has a market cap of 7.3B. Regarding current trading prices, BGNE is priced at $184.71, while RVMD trades at $39.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RVMD's P/E ratio is -9.83. In terms of profitability, BGNE's ROE is -0.12%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, BGNE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, HALO has a market cap of 6.9B. Regarding current trading prices, BGNE is priced at $184.71, while HALO trades at $56.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas HALO's P/E ratio is 14.91. In terms of profitability, BGNE's ROE is -0.12%, compared to HALO's ROE of +1.22%. Regarding short-term risk, BGNE is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, VRNA has a market cap of 6.9B. Regarding current trading prices, BGNE is priced at $184.71, while VRNA trades at $81.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas VRNA's P/E ratio is -40.60. In terms of profitability, BGNE's ROE is -0.12%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, BGNE is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, JAZZ has a market cap of 6.7B. Regarding current trading prices, BGNE is priced at $184.71, while JAZZ trades at $108.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas JAZZ's P/E ratio is 14.68. In terms of profitability, BGNE's ROE is -0.12%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, BGNE is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BGNE is priced at $184.71, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RETA's P/E ratio is -66.29. In terms of profitability, BGNE's ROE is -0.12%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BGNE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BPMC has a market cap of 6.5B. Regarding current trading prices, BGNE is priced at $184.71, while BPMC trades at $101.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BPMC's P/E ratio is -37.38. In terms of profitability, BGNE's ROE is -0.12%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, BGNE is less volatile compared to BPMC. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BBIO has a market cap of 6.5B. Regarding current trading prices, BGNE is priced at $184.71, while BBIO trades at $34.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BBIO's P/E ratio is -9.62. In terms of profitability, BGNE's ROE is -0.12%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, BGNE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MDGL has a market cap of 6.1B. Regarding current trading prices, BGNE is priced at $184.71, while MDGL trades at $274.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MDGL's P/E ratio is -15.46. In terms of profitability, BGNE's ROE is -0.12%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, BGNE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, TLX has a market cap of 5.6B. Regarding current trading prices, BGNE is priced at $184.71, while TLX trades at $16.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas TLX's P/E ratio is 184.67. In terms of profitability, BGNE's ROE is -0.12%, compared to TLX's ROE of +0.14%. Regarding short-term risk, BGNE is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, TGTX has a market cap of 5.6B. Regarding current trading prices, BGNE is priced at $184.71, while TGTX trades at $35.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas TGTX's P/E ratio is 140.44. In terms of profitability, BGNE's ROE is -0.12%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, BGNE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BGNE is priced at $184.71, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BGNE's ROE is -0.12%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BGNE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BGNE is priced at $184.71, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BGNE's ROE is -0.12%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BGNE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, NUVL has a market cap of 5.4B. Regarding current trading prices, BGNE is priced at $184.71, while NUVL trades at $74.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas NUVL's P/E ratio is -16.86. In terms of profitability, BGNE's ROE is -0.12%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, BGNE is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IONS has a market cap of 5.3B. Regarding current trading prices, BGNE is priced at $184.71, while IONS trades at $33.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IONS's P/E ratio is -11.21. In terms of profitability, BGNE's ROE is -0.12%, compared to IONS's ROE of -0.92%. Regarding short-term risk, BGNE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, BGNE is priced at $184.71, while AXSM trades at $105.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas AXSM's P/E ratio is -18.22. In terms of profitability, BGNE's ROE is -0.12%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, BGNE is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, BGNE is priced at $184.71, while ALKS trades at $30.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ALKS's P/E ratio is 14.58. In terms of profitability, BGNE's ROE is -0.12%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, BGNE is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ADMA has a market cap of 4.7B. Regarding current trading prices, BGNE is priced at $184.71, while ADMA trades at $19.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ADMA's P/E ratio is 23.62. In terms of profitability, BGNE's ROE is -0.12%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, BGNE is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BGNE's ROE is -0.12%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, BGNE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BGNE is priced at $184.71, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas OPT's P/E ratio is -1.52. In terms of profitability, BGNE's ROE is -0.12%, compared to OPT's ROE of +2.60%. Regarding short-term risk, BGNE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, BGNE is priced at $184.71, while PCVX trades at $32.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas PCVX's P/E ratio is -8.15. In terms of profitability, BGNE's ROE is -0.12%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, BGNE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BGNE is priced at $184.71, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BGNE's ROE is -0.12%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BGNE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, AKRO has a market cap of 4B. Regarding current trading prices, BGNE is priced at $184.71, while AKRO trades at $49.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas AKRO's P/E ratio is -13.24. In terms of profitability, BGNE's ROE is -0.12%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, BGNE is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RYTM has a market cap of 3.9B. Regarding current trading prices, BGNE is priced at $184.71, while RYTM trades at $61.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RYTM's P/E ratio is -21.06. In terms of profitability, BGNE's ROE is -0.12%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, BGNE is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRUS has a market cap of 3.9B. Regarding current trading prices, BGNE is priced at $184.71, while MRUS trades at $56.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MRUS's P/E ratio is -13.49. In terms of profitability, BGNE's ROE is -0.12%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, BGNE is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, PTCT has a market cap of 3.8B. Regarding current trading prices, BGNE is priced at $184.71, while PTCT trades at $48.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas PTCT's P/E ratio is 7.45. In terms of profitability, BGNE's ROE is -0.12%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, BGNE is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BGNE is priced at $184.71, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BGNE's ROE is -0.12%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BGNE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RNA has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while RNA trades at $30.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RNA's P/E ratio is -10.05. In terms of profitability, BGNE's ROE is -0.12%, compared to RNA's ROE of -0.27%. Regarding short-term risk, BGNE is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BGNE's ROE is -0.12%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BGNE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CYTK has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while CYTK trades at $31.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CYTK's P/E ratio is -5.67. In terms of profitability, BGNE's ROE is -0.12%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, BGNE is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SLNO has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while SLNO trades at $73.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SLNO's P/E ratio is -15.47. In terms of profitability, BGNE's ROE is -0.12%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, BGNE is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SRPT has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while SRPT trades at $37.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SRPT's P/E ratio is -13.72. In terms of profitability, BGNE's ROE is -0.12%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, BGNE is less volatile compared to SRPT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KRYS has a market cap of 3.6B. Regarding current trading prices, BGNE is priced at $184.71, while KRYS trades at $125.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KRYS's P/E ratio is 30.21. In terms of profitability, BGNE's ROE is -0.12%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, BGNE is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, BGNE is priced at $184.71, while ACAD trades at $21.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ACAD's P/E ratio is 15.52. In terms of profitability, BGNE's ROE is -0.12%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, BGNE is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while SWTX trades at $46.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SWTX's P/E ratio is -13.70. In terms of profitability, BGNE's ROE is -0.12%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, BGNE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ACLX has a market cap of 3.4B. Regarding current trading prices, BGNE is priced at $184.71, while ACLX trades at $62.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ACLX's P/E ratio is -20.74. In terms of profitability, BGNE's ROE is -0.12%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, BGNE is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RARE has a market cap of 3.2B. Regarding current trading prices, BGNE is priced at $184.71, while RARE trades at $34.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RARE's P/E ratio is -5.84. In terms of profitability, BGNE's ROE is -0.12%, compared to RARE's ROE of -1.86%. Regarding short-term risk, BGNE is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CRSP has a market cap of 3.1B. Regarding current trading prices, BGNE is priced at $184.71, while CRSP trades at $36.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CRSP's P/E ratio is -8.08. In terms of profitability, BGNE's ROE is -0.12%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, BGNE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, BGNE is priced at $184.71, while CPRX trades at $24.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CPRX's P/E ratio is 15.89. In terms of profitability, BGNE's ROE is -0.12%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, BGNE is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, BGNE is priced at $184.71, while VKTX trades at $26.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas VKTX's P/E ratio is -23.10. In terms of profitability, BGNE's ROE is -0.12%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, BGNE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, PTGX has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while PTGX trades at $47.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas PTGX's P/E ratio is 60.86. In terms of profitability, BGNE's ROE is -0.12%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, BGNE is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MORF's P/E ratio is -14.88. In terms of profitability, BGNE's ROE is -0.12%, compared to MORF's ROE of -0.22%. Regarding short-term risk, BGNE is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MOR's P/E ratio is -12.64. In terms of profitability, BGNE's ROE is -0.12%, compared to MOR's ROE of +2.51%. Regarding short-term risk, BGNE is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while CRNX trades at $30.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CRNX's P/E ratio is -8.02. In terms of profitability, BGNE's ROE is -0.12%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, BGNE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MTSR has a market cap of 2.8B. Regarding current trading prices, BGNE is priced at $184.71, while MTSR trades at $26.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MTSR's P/E ratio is -10.57. In terms of profitability, BGNE's ROE is -0.12%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, BGNE is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SRRK has a market cap of 2.8B. Regarding current trading prices, BGNE is priced at $184.71, while SRRK trades at $29.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SRRK's P/E ratio is -11.38. In terms of profitability, BGNE's ROE is -0.12%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, BGNE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, BGNE is priced at $184.71, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KDNY's P/E ratio is -12.47. In terms of profitability, BGNE's ROE is -0.12%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, BGNE is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, LEGN has a market cap of 2.7B. Regarding current trading prices, BGNE is priced at $184.71, while LEGN trades at $28.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas LEGN's P/E ratio is -24.53. In terms of profitability, BGNE's ROE is -0.12%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, BGNE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, BGNE is priced at $184.71, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MYOV's P/E ratio is -14.05. In terms of profitability, BGNE's ROE is -0.12%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, BGNE is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IMVT has a market cap of 2.5B. Regarding current trading prices, BGNE is priced at $184.71, while IMVT trades at $14.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IMVT's P/E ratio is -5.45. In terms of profitability, BGNE's ROE is -0.12%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, BGNE is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MLTX has a market cap of 2.5B. Regarding current trading prices, BGNE is priced at $184.71, while MLTX trades at $38.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MLTX's P/E ratio is -16.93. In terms of profitability, BGNE's ROE is -0.12%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, BGNE is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, BGNE is priced at $184.71, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas PRVB's P/E ratio is -16.43. In terms of profitability, BGNE's ROE is -0.12%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, BGNE is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while IBRX trades at $2.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IBRX's P/E ratio is -4.67. In terms of profitability, BGNE's ROE is -0.12%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, BGNE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas LBPH's P/E ratio is -26.66. In terms of profitability, BGNE's ROE is -0.12%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, BGNE is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas DICE's P/E ratio is -21.91. In terms of profitability, BGNE's ROE is -0.12%, compared to DICE's ROE of +0.56%. Regarding short-term risk, BGNE is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BCRX has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while BCRX trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BCRX's P/E ratio is -41.31. In terms of profitability, BGNE's ROE is -0.12%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, BGNE is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while ARWR trades at $16.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ARWR's P/E ratio is -12.95. In terms of profitability, BGNE's ROE is -0.12%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, BGNE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, XENE has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while XENE trades at $28.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas XENE's P/E ratio is -8.96. In terms of profitability, BGNE's ROE is -0.12%, compared to XENE's ROE of -0.32%. Regarding short-term risk, BGNE is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MIRM has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while MIRM trades at $44.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MIRM's P/E ratio is -27.61. In terms of profitability, BGNE's ROE is -0.12%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, BGNE is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while APGE trades at $36.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas APGE's P/E ratio is -10.15. In terms of profitability, BGNE's ROE is -0.12%, compared to APGE's ROE of -0.19%. Regarding short-term risk, BGNE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CALT's P/E ratio is -22.73. In terms of profitability, BGNE's ROE is -0.12%, compared to CALT's ROE of -1.67%. Regarding short-term risk, BGNE is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BLTE has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while BLTE trades at $65.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BLTE's P/E ratio is -48.15. In terms of profitability, BGNE's ROE is -0.12%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, BGNE is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, APLS has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while APLS trades at $16.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas APLS's P/E ratio is -9.10. In terms of profitability, BGNE's ROE is -0.12%, compared to APLS's ROE of -1.00%. Regarding short-term risk, BGNE is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, AAPG has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while AAPG trades at $24.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas AAPG's P/E ratio is -32.97. In terms of profitability, BGNE's ROE is -0.12%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, BGNE is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while VCYT trades at $26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas VCYT's P/E ratio is 63.36. In terms of profitability, BGNE's ROE is -0.12%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, BGNE is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while VCEL trades at $41.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas VCEL's P/E ratio is 825.90. In terms of profitability, BGNE's ROE is -0.12%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, BGNE is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, NAMS has a market cap of 2B. Regarding current trading prices, BGNE is priced at $184.71, while NAMS trades at $18.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas NAMS's P/E ratio is -9.86. In terms of profitability, BGNE's ROE is -0.12%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, BGNE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, BGNE is priced at $184.71, while KNSA trades at $27.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KNSA's P/E ratio is -114.00. In terms of profitability, BGNE's ROE is -0.12%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, BGNE is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, HRMY has a market cap of 2B. Regarding current trading prices, BGNE is priced at $184.71, while HRMY trades at $34.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas HRMY's P/E ratio is 13.17. In terms of profitability, BGNE's ROE is -0.12%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, BGNE is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, LGND has a market cap of 2B. Regarding current trading prices, BGNE is priced at $184.71, while LGND trades at $102.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas LGND's P/E ratio is -14.02. In terms of profitability, BGNE's ROE is -0.12%, compared to LGND's ROE of -0.16%. Regarding short-term risk, BGNE is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CGON has a market cap of 2B. Regarding current trading prices, BGNE is priced at $184.71, while CGON trades at $25.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CGON's P/E ratio is -17.10. In terms of profitability, BGNE's ROE is -0.12%, compared to CGON's ROE of -0.17%. Regarding short-term risk, BGNE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, NAMSW has a market cap of 1.9B. Regarding current trading prices, BGNE is priced at $184.71, while NAMSW trades at $7.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas NAMSW's P/E ratio is N/A. In terms of profitability, BGNE's ROE is -0.12%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, BGNE is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KYMR has a market cap of 1.9B. Regarding current trading prices, BGNE is priced at $184.71, while KYMR trades at $29.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KYMR's P/E ratio is -9.06. In terms of profitability, BGNE's ROE is -0.12%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, BGNE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, DNLI has a market cap of 1.9B. Regarding current trading prices, BGNE is priced at $184.71, while DNLI trades at $13.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas DNLI's P/E ratio is -4.96. In terms of profitability, BGNE's ROE is -0.12%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, BGNE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, GLPG has a market cap of 1.9B. Regarding current trading prices, BGNE is priced at $184.71, while GLPG trades at $28.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas GLPG's P/E ratio is -9.28. In terms of profitability, BGNE's ROE is -0.12%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, BGNE is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BLU has a market cap of 1.9B. Regarding current trading prices, BGNE is priced at $184.71, while BLU trades at $14.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BLU's P/E ratio is -20.20. In terms of profitability, BGNE's ROE is -0.12%, compared to BLU's ROE of -0.22%. Regarding short-term risk, BGNE is more volatile compared to BLU. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.